Invention patent applications and grants in China. by Pu Miao (12886949)

Subjects:

Regression results of the different number of patents. by Pu Miao (12886949)

Subjects:

Sensitivity analysis of parallel trend with relative deviation limits. by Pu Miao (12886949)

Subjects:

Instrumental variable regression results. by Pu Miao (12886949)

Subjects:

Other robust regression results. by Pu Miao (12886949)

Subjects:

Baseline regression results. by Pu Miao (12886949)

Subjects:

Results of propensity score matching. by Pu Miao (12886949)

Subjects:

Regression results of different types of talent policies. by Pu Miao (12886949)

Subjects:

Parallel trend test. by Pu Miao (12886949)

Subjects:

Placebo test. by Pu Miao (12886949)

Subjects:

Regression results of enterprise property rights samples. by Pu Miao (12886949)

Subjects:

Regression results of talent policies with different levels of support. by Pu Miao (12886949)

Subjects:

Regression results of enterprise R&D investment samples. by Pu Miao (12886949)

Subjects:

Regression results on the interaction between talent policies. by Pu Miao (12886949)

Subjects:

Sensitivity analysis of parallel trend under smoothing restrictions. by Pu Miao (12886949)

Subjects:

Descriptive statistics of variables. by Pu Miao (12886949)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

“…Among the letrozole-treated patients, the mean FIB-4 index tended to decline during letrozole treatment; a significant decrease was observed at 18 and 24 months compared with the baseline values (p = 0.044 and p = 0.013). …”

S1 Data - by Kazuyoshi Ohkawa (836847)

“…Among the letrozole-treated patients, the mean FIB-4 index tended to decline during letrozole treatment; a significant decrease was observed at 18 and 24 months compared with the baseline values (p = 0.044 and p = 0.013). …”

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)